నైరూప్య

Effect on ischemia modified albumin in lipitensive patients.

Kuldip Singh

Background: Lipitensive are well established leading causes of morbidity and mortality worldwide. A prompt diagnosis and treatment of lipitensive is pivotal for a better health care. Albumin is the most important protein synthesized by the liver. Posttranscriptional changes occur in the molecular structure of albumin due to various factors and isoforms arise. Ischemic Modified Albumin (IMA) is one such isoform.

Aim: The aim of the study was to evaluate the changes in serum ischemia modified albumin in lipitensive patients.

Materials and Methods: 30 lipitensive patients (study group) and equal number of healthy normal subjects as a control group were recruited from the rural and urban community of Punjab origin after taken prior consent of participants. After overnight fasting, venous blood samples were taken from lipitensive and healthy control subjects for the estimation of ischemia modified albumin along with complete lipid profile, fasting glucose and HbA1C levels.

Results: IMA was significantly increased from 121.15 ± 19.36 μM/L to 277.67 ± 21.98 μM/L by 129.19% in lipitensive patients in comparison to healthy normal subjects.

Conclusion: A progressive enhancement in serum IMA level suggested that IMA as a sensitive and early biomarker might be useful for optimal treatment of the lipitensive patients.